United States - English - NLM (National Library of Medicine)

otsuka america pharmaceutical, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify (aripiprazole) oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: - schizophrenia - acute treatment of manic and mixed episodes associated with bipolar i disorder - adjunctive treatment of major depressive disorder - irritability associated with autistic disorder - treatment of tourette's disorder abilify injection is indicated for the treatment of: - agitation associated with schizophrenia or bipolar mania abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including abilify, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhea

Singapore - English - HSA (Health Sciences Authority)

lundbeck singapore pte. ltd. - sterile aripiprazole monohydrate 416mg/vial equivalent to anhydrous aripiprazole - injection, powder, for suspension, extended release - sterile aripiprazole monohydrate 416mg/vial equivalent to anhydrous aripiprazole 400mg/vial

United States - English - NLM (National Library of Medicine)

stat rx usa llc - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify is indicated for the treatment of schizophrenia. the efficacy of abilify was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents [see clinical studies (14.1)] . monotherapy abilify is indicated for the acute and maintenance treatment of manic and mixed episodes associated with bipolar i disorder. efficacy was established in four 3-week monotherapy trials in adults and one 4-week monotherapy trial in pediatric patients (10 to 17 years). maintenance efficacy was demonstrated in a monotherapy trial in adults and can be extrapolated to pediatric patients (10 to 17 years) [see clinical studies (14.2)] . adjunctive therapy abilify is indicated as an adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with bipolar i disorder. efficacy was established in one 6-week adjunctive trial in adults and can be e

United States - English - NLM (National Library of Medicine)

rebel distributors corp. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 5 mg - abilify is indicated for the treatment of schizophrenia. the efficacy of abilify was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents [see clinical studies (14.1)] . monotherapy abilify is indicated for the acute and maintenance treatment of manic and mixed episodes associated with bipolar i disorder. efficacy was established in four 3-week monotherapy trials in adults and one 4-week monotherapy trial in pediatric patients (10 to 17 years). maintenance efficacy was demonstrated in a monotherapy trial in adults and can be extrapolated to pediatric patients (10 to 17 years) [see clinical studies (14.2)] . adjunctive therapy abilify is indicated as an adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with bipolar i disorder. efficacy was established in one 6-week adjunctive trial in adults and can be e

United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 5 mg - abilify is indicated for the treatment of schizophrenia. the efficacy of abilify was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents [see clinical studies (14.1)] . acute treatment of manic and mixed episodes abilify is indicated for the acute treatment of manic and mixed episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or valproate. efficacy as monotherapy was established in four 3-week monotherapy trials in adults and one 4-week monotherapy trial in pediatric patients (10 to 17 years). efficacy as adjunctive therapy was established in one 6-week adjunctive trial in adults [see clinical studies (14.2)] . maintenance treatment of bipolar i disorder abilify is indicated for the maintenance treatment of bipolar i disorder, both as monotherapy and as an adjunct to either lithium or valproate. maintenance efficacy was

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify is indicated for the treatment of schizophrenia. the efficacy of abilify was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents [see clinical studies (14.1)] . acute treatment of manic and mixed episodes abilify is indicated for the acute treatment of manic and mixed episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or valproate. efficacy as monotherapy was established in four 3-week monotherapy trials in adults and one 4-week monotherapy trial in pediatric patients (10 to 17 years). efficacy as adjunctive therapy was established in one 6-week adjunctive trial in adults [see clinical studies (14.2)] . maintenance treatment of bipolar i disorder abilify is indicated for the maintenance treatment of bipolar i disorder, both as monotherapy and as an adjunct to either lithium or valproate. maintenance efficacy was

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 10 mg - abilify oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: - schizophrenia [see clinical studies (14.1)] - acute treatment of manic and mixed episodes associated with bipolar i disorder [see clinical studies (14.2)] - adjunctive treatment of major depressive disorder [see clinical studies (14.3)] - irritability associated with autistic disorder [see clinical studies (14.4)] - treatment of tourette's disorder [see clinical studies (14.5)] abilify injection is indicated for the treatment of: - agitation associated with schizophrenia or bipolar mania [see clinical studies (14.6)] abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see

European Union - English - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - aripiprazole - schizophrenia - psycholeptics - maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

otsuka pharmaceutical co., ltd. - aripiprazole - yellow tablet, diameter: 8 mm, thickness: 2.8 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

otsuka pharmaceutical co., ltd. - aripiprazole - slightly reddish-white tablet, diameter: 6 mm, thickness: 2.5 mm